Constitutive nuclear factor-kappa B mRNA, protein overexpression and enhanced DNA-binding activity in thymidylate synthase inhibitor-resistant tumour cells by Wang, W & Cassidy, J
Constitutive nuclear factor-kappa B mRNA, protein
overexpression and enhanced DNA-binding activity in thymidylate
synthase inhibitor-resistant tumour cells
W Wang*
,1,2 and J Cassidy
2
1Department of Medicine and Therapeutics, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK;
2Department of
Medical Oncology, University of Glasgow, Switchback Road, Glasgow G61 1BD, UK
In this study, the gene copy number, mRNA and protein expression levels and nuclear DNA-binding activity of nuclear factor kappa B
(NF-kB) were compared in a panel of five pairs of thymidylate synthase (TS) inhibitor-resistant and wild-type parent cancer cell lines.
High constitutive NF-kB DNA-binding activity was detected in all chemoresistant cell lines. The upregulated NF-kB activity was
composed of NF-kB subunits p50 and p65. Four out of five resistant cell lines constitutively overexpressed NF-kB p50 and p65
mRNA and protein. One resistant cell line with the highest NF-kB DNA-binding activity showed normal p50 and p65 protein
expression. No NF-kB gene amplification was detected in resistant cell lines. Transient exposure of wild-type RKOWT and H630WT
cells to 5-FU induced NF-kB DNA-binding activity but had no effect on NF-kB protein expression in these cells. Our results indicate
that high constitutive NF-kB activity caused by its gene overexpression is an intrinsic character of TS inhibitor-resistant cells. NF-kB
can antagonise anticancer drug-induced apoptosis. High NF-kB expression and nuclear activity in TS inhibitor-resistant cancer cells
may play an important role in the chemoresistance.
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The production of the pyrimidine nucleotide TMP from deoxy-
uridine monophosphate is a critical step in the de novo pathway of
DNA synthesis. Since this reaction is catalysed by thymidylate
synthase (TS, EC 2.1.1.45) using folate cosubstrate 5, 10-methylene
tetrahydrofolate and is the only source of de novo cellular
thymidylate, it makes TS an attractive molecular target for
cytotoxic drugs (Jackman and Calvert, 1995; Rustum et al, 1997).
TS inhibitors (5-fluorourocil (5-FU) and tomudex (TDX)) block TS
activity and have been effectively used in the treatment of human
solid tumours such as colorectal, breast and lung cancers (Burris
et al, 1994; Cunningham et al, 1994; Smith et al, 2002). As with
other anticancer drugs, acquired or inherent resistance to these
drugs is still one of the main barriers for their clinical use. Apart
from high levels of TS protein expression (Jackman et al, 1995), the
other molecular mechanisms of TS-inhibitor-resistance are still
largely unknown.
Nuclear factor-kappaB (NF-kB) is a transcription factor that is
composed of five subunits (p50/p105, p52/p100, p65 (RelA), RelB
and c-Rel). NF-kB can bind to DNA target sites (kB sites) and
influence downstream gene expression (Perkins, 2000). The
inhibitor of kB( I kB) is a natural inhibitor of NF-kB. In most
normal cells, IkB binds to NF-kB and retains NF-kB in the
cytoplasm as an inactive complex. Many chemical and biological
stimuli can induce IkB phosphorylation, ubiquitinisation and
subsequent degradation. NF-kB will be released from the NF-kB–
IkB complex and translocated into the nucleus. The liberated NF-
kB then binds to the promoter region of the relevant downstream
genes and triggers a series of transcriptional events (Karin, 1999).
Some anticancer drugs, cytokines and radiation can induce NF-
kB activity in cancer cells (Baldwin Jr, 1996; Pahl, 1999). NF-kB
antagonises the cytotoxicity of some anticancer drugs by inducing
the expression of anti-apoptotic genes (e.g. c-IAPs, IXAP, A1/Bfl-1
and IEX-IL) (Wang et al, 1998, 1999b; Wu et al, 1998). Human
cancer cells with induced NF-kB nuclear activity have demon-
strated resistance to apoptosis induced by chemotherapy or
radiotherapy (Barkett and Gilmore, 1999; Rayet and Gelinas,
1999; Baldwin Jr, 2001; Yamamoto and Gaynor, 2001). Transfection
of mutant super-repressor IkBa into tumour cell lines can inhibit
NF-kB activity and enhance the cytotoxicity of anticancer drugs in
vitro (Wang et al, 1996) and in vivo (Wang et al, 1999a; Cusack
et al, 2001).
In this study, nuclear NF-kB activity, the protein and mRNA
expression levels of NF-kB in five pairs of TS inhibitor-resistant
and sensitive cell lines were tested. The results demonstrate that
constitutive high nuclear NF-kB activity and overexpression of NF-
kB protein and mRNA are intrinsic characteristics of TS inhibitor-
resistant cell lines.
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sMATERIALS AND METHODS
Cell culture
Three TDX-resistant cell lines (colorectal tumour: H630TDX and
RKOTDX; lymphoblastoid: W1L2TDX), two 5-FU-resistant colorectal
cancer cell lines (H6305-FU and R105-FU) and the relevant parent
cell lines were chosen for this study (The chemoresistant cell lines
were kindly provided by Professor PG Johnston, Department of
Oncology, The Queen’s University of Belfast). The characteristics
and culturing conditions have been described previously (Boon-
song et al, 2000; Wang et al, 2001). To rule out induction of NF-kB
by the maintenance dose of 5-FU/TDX, all drug-resistant cells were
cultured in drug-free RPMI 1640 medium supplemented with 10%
fetal calf serum, 50Uml
 1 penicillin, 50mgml
 1 streptomycin for
10 days before harvesting by trypsinisation for further analysis.
Electrophoretic mobility-shift assays (EMSA)
The nuclear and cytoplasmic protein extraction and EMSA were
carried out as previously described (Wang et al, 1996). The nuclear
extract (5mg) was incubated with 1mg poly(dIdC) (Sigma-Aldrich,
Dorset, UK) in binding buffer (50mM Tris (pH 7.6), 250mM KCl,
25mM DTT, 5mM EDTA and 25% glycerol) for 10min at room
temperature (RT). Approximately 20000c.p.m. of
32P-labelled 22-
mer double-stranded NF-kB DNA probe (50-AGTTGAGGG-
GACTTTCCCAGGC-30) was added and incubated at RT for
20min. Oct-1 (50-TGTCGAATGCAAATCACTAGAA-30) was used
as loading control for EMSA. The EMSA conditions of Oct-1 were
the same as those for NF-kB. For supershift assay and binding
specificity determination, 5mg of nuclear extract mixture from
different resistant cell lines was incubated with 0.4mg2ml
 1 of NF-
kB p65 or p50 antibody (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) or 20 wild-type or mutant (50-AGTTGATATTACTTT-
TATAGGC-30) unlabelled NF-kB probe for 30min before EMSA
analysis. The complexes were separated on a 6% polyacrylamide
gel and exposed for autoradiography.
Western blot analysis
The cytoplasmic protein (40mglane
 1) was electrophoresed
through a 10% SDS–PAGE and transferred to a PVDF membrane
(Millipore, UK). The blots were stained with rabbit polyclonal
primary (p50, 1:500; p65 and IkBa, 1:200; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) and HRP-conjugated donkey anti-
rabbit secondary (1:5000; Amersham Pharmacia Biotech, NJ,
USA) antibodies, respectively, for 1h at RT. The loading quantity
of protein was verified by staining the same membranes with
monoclonal anti-a-tubulin or antivinculin antibody (Sigma-
Aldrich, Dorset, UK; anti-a-tubulin: 1:2000; antivinculin:
1:1000) and HRP-conjugated sheep anti-mouse secondary anti-
body (1:5000; Amersham Pharmacia Biotech, NJ, USA). The signal
was detected using an ECL Western blotting detection kit
(Amersham Pharmacia Biotech, NJ, USA). The intensity of the
bands was scanned and analysed using Molecular Analyst software
(Bio-Rad Laboratories, CA, USA). This programme was also used
to analyse the band intensity of Northern and Southern blots.
Northern blot analysis
Total RNA was extracted using the previously described method
(Wang et al, 2001). Briefly, cells (B5 10
6) were digested in
denaturing buffer and protein was extracted twice with phenol (pH
4.3):chloroform (1:0.3). Total RNA in the aqueous phase was
precipitated with an equal volume of isopropanol and then washed
with 70% ethanol. Total RNA (20mg) from drug-sensitive and
resistant cells was electrophoresed through a 1% agarose gel
containing 1.9% formaldehyde. After transfer to a Hybond-N
+
nylon membrane (Amersham), the blotted RNA was immobilised
by exposing under 250nm UV light for 3min. Membranes were
hybridised with [
32P] dATP random labelled probes at 681C
overnight. The signals were detected by exposing the membranes
to a FUJI Phosphor Plate overnight and scanned using a FUJI
FILM-3000 Phosphor-Imager. Blots were stripped and rehybri-
dised with different probes. NF-kB p50 and p65 subunits were
subjected to Northern blotting analysis and GAPDH gene was used
as an internal control. The probes were reverse transcribed and
amplified from 1mg RKOTDX total RNA using a one-step RT–PCR
kit (Promega, CA, USA). The sequences of primers are as follows:
NF-kB p50 (601bp): forward 50-CTGGTGATCGTGGAACAGCC-30;
reverse 50-CAGAGCCTGCTGTCTTGTCC-30; NF-kB p65 (659bp):
forward 50-ATGCGCTTCCGCTACAAGTG-30; reverse 50-
ACAATGGCCACTTGTCGGTG-30; GAPDH (915bp): forward 50-
AAGGTCGGAGTCAACGGATTTG-30; reverse 50-CTTGA-
CAAAGTGGTCGTTGAGG-30. The sequence of each amplified
probe was confirmed by direct automated DNA sequencing.
Southern blot analysis
The DNA was extracted using Nucleon DNA purification kit
(Nucleonbiosciences, Glasgow, UK) following the supplier’s in-
struction. A total of 20mg of DNA from each cell line was digested
with MvaII (p50) or SacI (p65) for 3h at 371C. The digested DNA
fragments were separated through a 0.6% agarose gel. After de-
naturing in 0.1N NaOH, the DNA was blotted onto a nylon mem-
brane by overnight capillary transfer and fixed under 250nm UV
light for 3min. The probes, hybridisation and image analysis con-
ditions were the same as those for Northern blotting analysis. The
same membrane was stripped and hybridised to different probes.
RESULTS
Higher constitutive nuclear NF-jB activity in TS inhibitor-
resistant cells
NF-kB nuclear activity was tested in five pairs of TS inhibitors (5-
FU and TDX)-sensitive and -resistant cell lines. All resistant cell
lines were cultured in drug-free medium for 10 days before EMSA
analysis. There was substantial NF-kB activity in the chemosensi-
tive parent cell lines, but the TS inhibitor-resistant cell lines
demonstrated much higher nuclear NF-kB activity (Figure 1A).
The ratio of NF-kB nuclear activity in paired resistant and wild-
type cell lines ranged from 1.8 to 3.5 (Figure 1B). To verify the
bands, 5mg of nuclear extract mixture from resistant cell lines was
preincubated with 20 times higher concentration of unlabelled
wild-type or mutant NF-kB probe, before EMSA. The retarded
bands were removed by unlabelled wild-type NF-kB probe but not
the mutant one (Figure 1C, lanes 4 and 5). Supershift analysis
showed that NF-kB p50 and p65 were involved in the constitutive
NF-kB activity in the resistant cells (Figure 1C, lanes 2 and 3). No
supershift band was observed by using antibodies against NF-kB
subunits p52, c-Rel and RelB (data not shown). Anti-VEGF
antibody was used as a negative control for the supershift assay.
To test if the high NF-kB nuclear activity in drug-resistant cells
was caused by IkBa degradation, IkBa protein levels in drug-
sensitive and -resistant cells were assessed by Western blotting
analysis. It seems that IkBa degradation was not responsible for
the high constitutive NF-kB nuclear activity in resistant cells
because high and comparable IkBa protein levels were detected in
both resistant and relevant parent cell lines (Figure 1D).
Constitutive overexpression of NF-jB subunits p50 and
p65 protein and mRNA in TS inhibitor-resistant cell lines
Constitutively upregulated transcription factor activity is fre-
quently caused by gene overexpression (Adams and Kaelin, 1996).
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p50 and p65 in drug-resistant cell lines. As shown in Figure 2, p50
and p65 protein and mRNA were 1.5 to three-fold constitutively
overexpressed in all TS inhibitor-resistant cell lines except for
H630TDX cells in which both proteins were only slightly
upregulated. These results indicate that although high NF-kB
nuclear DNA-binding activity is mainly caused by enhanced
nuclear translocation and DNA-binding affinity, transcriptional
and translational deregulation may also play a role in the
maintenance of high constitutive NF-kB nuclear activity in TS
inhibitor-resistant cells. We have demonstrated before that the
constitutive TS gene overexpression in these cell lines was
accompanied by gene amplification (Wang et al, 2001). We
therefore tested if the high constitutive NF-kB activity in these cell
lines was also caused by gene amplification. Gene copy number of
NF-kB p50 and p65 was detected by Southern blotting analysis. As
demonstrated in the bottom panel of Figure 2A, compared with
relevant parent cell lines, no p50 and p65 gene amplification was
detected in the drug-resistant cell lines. The change of NF-kB
DNA-binding activity in most drug-resistant cell lines was parallel
to the increased p50 and p65 protein expression levels. In contrast,
the DNA-binding activity in H630TDX cells was most highly
upregulated but the expression of p50 and p65 proteins in this cell
line was maintained at similar levels to those of the parent cell line
(Figure 2B).
Transient exposure of cancer cells to 5-FU induced NF-jB
nuclear DNA-binding activity but not the expression of
NF-jB p50 and p65 protein
Anticancer drugs exposure can induce NF-kB activity in cancer cell
lines (Yamamoto and Gaynor, 2001). To test the effect of 5-FU on
NF-kB DNA-binding activity and protein expression levels, colo-
rectal cancer cell lines H630WT and RKOWT were exposed to 5-FU
at different concentrations and time lengths. Figure 3A demon-
strates that NF-kB DNA-binding activity was induced by 5-FU in
both a time- and concentration-dependent manner in both
H630WT and RKOWT cell lines, whereas exposure of these cells to
30mM 5-FU up to 24h had no effect on the expression levels of
both NF-kB p50 and p65 proteins in the tested cell lines.
DISCUSSION
5-FU and TDX have been successfully used in human solid cancer
chemotherapy. Both drugs inhibit TS, the enzyme converting 20-
deoxyuridine to thymidylate by reductive methylation. 5-FU can
also induce metabolic disruption and cell death by incorporating
into DNA and RNA. After chemotherapy, some cancer cells show
acquired chemoresistance to TS inhibitors. The drug-resistant cells
usually demonstrate TS protein and mRNA overexpression and TS
gene amplification (Wang et al, 2001). Alternative molecular
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Figure 1 High constitutive NF-kB DNA-binding activity in 5-FU- and TDX-resistant cell lines. (A) An equal amount (5mg) of nuclear extract was
subjected to EMSA. All drug-resistant cells demonstrate higher nuclear NF-kB activity. The constitutively activated transcription factor, Oct-1, was used as a
protein loading control. (B) Ratio of NF-kB DNA-binding activity between resistant and relevant parent cell lines. (C) Probe specificity and supershift analysis
of NF-kB activity in drug-resistant cells. An equal amount (5mg) of mixed nuclear extract from resistant cell lines was incubated with NF-kB p50 and p65
antibodies or unlabelled NF-kB probes before EMSA analysis. (D)I kBa protein levels were determined in cytoplasmic extract (40mglane
 1) using Western
blotting analysis. The protein loading control was monitored by staining the same membrane with antivinculin antibody (lower panel).
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elucidated. In this study, we demonstrated high NF-kB DNA-
binding activity in a panel of five TS inhibitor-resistant cell lines.
NF-kB in resistant cell lines was composed of p65/p50 and p50/p50
dimers, which are the most common NF-kB dimers and play a
major antiapoptotic role in anticancer drug-treated mammalian
cells (Wang et al, 1996, 1999a; Cusack et al, 2000). Anticancer
drugs exposure can induce NF-kB activity in cancer cell lines
(Yamamoto and Gaynor, 2001). The half-life of NF-kB is less than
30min and maintenance of its activity requires ongoing protein
synthesis and continuous stimuli (Hohmann et al, 1991). To rule
out the possibility that the enhanced NF-kB DNA-binding activity
in resistant cell lines was also induced by the maintaining dose of
5-FU or TDX, the resistant cell lines were cultured in drug-free
medium for 10 days before EMSA. The cells demonstrated
comparable NF-kB DNA-binding activity whether or not they
were cultured in the medium with or without maintenance
concentrations of TS inhibitors (data not shown). In comparison
with relevant parent cell lines, drug-resistant cells demonstrated
higher NF-kB DNA-binding activity. Thus, the high NF-kB activity
in drug-resistant cells is a constitutive and intrinsic feature of the
resistant cell lines. NF-kB is a transcription factor that antagonises
apoptosis induced by some anticancer drugs (Yamamoto and
Gaynor, 2001). Cancer cells with high induced NF-kB activity show
a high expression of antiapoptotic gene products such as c-IAPs,
IXAP, A1/Bfl-1 and IEX-IL (Wang et al, 1998). In our study, high
NF-KB activity in TS-inhibitor resistant cell lines may at least
partially lead to their chemoresistance. Figure 3A demonstrates
that NF-kB activity could be induced by transient exposure of
colorectal cancer cell lines to 5-FU. In combination with 5-FU,
disulfiram, an NF-kB inhibitor, strongly enhances the cytotoxicity
of 5-FU and totally reverses 5-FU resistance in two 5-FU-resistant
colorectal cancer cell lines in vitro (Wang et al, 2002). Thus,
targeting NF-kB may be a new measure to overcome TS inhibitor
resistance.
High transcription factor activity in cancer cells is frequently
induced by gene amplification and/or overexpression (Adams and
Kaelin, 1996). In this study, we demonstrated that overexpression
of NF-kB p50 and p65 protein and mRNA was detected in four out
of five drug-resistant cell lines. The overexpressed NF-kB protein
levels in these cell lines were in parallel with those of enhanced NF-
kB nuclear binding activity. Thus, the constitutive gene over-
expression may be the main cause of the high NF-kB nuclear
activity in these cell lines. Although NF-kB DNA-binding activity
in drug-sensitive cancer cell lines could be induced by transient
exposure to 5-FU, no alteration of NF-kB protein levels was
observed in these cell lines (Figure 3A, B). These results indicate
that transient TS inhibitor exposure can only temporarily induce
NF-kB activity at a post-translational level. The constitutive
NF-kB nuclear activity supported by gene overexpression is the
intrinsic character of most TS inhibitor-resistant cancer cells. NF-
kB deregulation in drug-resistant cell lines is mainly at the
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Figure 2 Protein and mRNA overexpression but no gene amplification of NF-kB p50 and p65 in drug-resistant cell lines. (A) WB: Western blotting
analysis of cytoplasmic extract (40mglane
 1) using p50 and p65 antibodies; NB: Northern blotting analysis of total RNA from different cell lines; SB: genomic
DNA (20mg) was analysed by Southern blot after MvaII (p50) and SacI (p65) cut. Loading control: tubulin for WB and GAPDH for NB and SB. (B) Relative
protein and mRNA expression levels in resistant cell lines. The intensity of bands was analysed using Molecular Analyst software and standardised by relevant
parent cells.
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binding levels because no gene amplification was detected by
Southern blotting. We have tested mRNA expression patterns in
the same panel of cell lines using Atlas nylon membrane cDNA
array system before and could not identify the mRNA over-
expression of NF-kB p65 that was spotted on the array membrane
(Wang et al, 2001). This discrepancy may be caused by the
sensitivity of the array system, especially for detecting the
expression of low copy number genes.
Compared to other cell lines, the NF-kB DNA-binding activity
and protein expression patterns in H630TDX cells are intriguing.
NF-kB nuclear DNA-binding activity in H630TDX cells was highly
upregulated. The NF-kB proteins p50 and p65 in this cell line were
similar to those in the parent cells. Apart from gene over-
expression, high NF-kB nuclear activity can be caused by enhanced
nuclear translocation and DNA-binding affinity (Rayet and
Gelinas, 1999). It has recently been reported that NF-kB protein
phosphorylation also plays an important role in the regulation of
NF-kB DNA-binding and transcriptional activity (Ghosh and
Karin, 2002). Our results indicate that high constitutive NF-kB
activity in TS inhibitor-resistant cell lines may be caused by
different molecular mechanisms.
IkB degradation is thought to be a main reason for induction
and maintenance of high nuclear NF-kB activity (Chiao et al, 1994;
Karin, 1999). IkBa is the predominant member of the IkB family.
IkBa degradation was involved in 5-FU-induced NF-kB activation
in 5-FU-sensitive cell lines (Wang et al, 2002). However, in this
study, high NF-kB activity in TS inhibitor-resistant cells was not
conferred by degradation of IkBa. High levels of IkBa were
detected in all drug-resistant cancer cell lines that demonstrated
high nuclear NF-kB activity (Figure 1D). It was reported that
constitutive nuclear NF-kB activity in two chemoresistant
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Figure 3 5-FU induced NF-kB DNA-binding activity but had no effect on the protein expression of NF-kB p50 and p65 in H630WT and RKOWT cells.
After exposure of cancer cells to 5-FU at different concentrations and time lengths, NF-kB DNA-binding activity and NF-kB p50 and p65 protein expression
levels were tested by EMSA (A) and Western blot (B), respectively. Oct-1 and vinculin were used as loading control for EMSA and Western blotting,
respectively.
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and overexpression of defective IkBa (Krappmann et al, 1999). The
role of IkBa in NF-kB signalling pathways in TS inhibitor-resistant
cell lines remains to be elucidated.
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